Bethlehem, PA, March 12, 2012 – Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today it has entered into a distribution agreement with INyDIA Labs, based in Madrid, Spain, for My5-FU™, a test that measures levels of a widely-used anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients.
http://www.lsgpa.com/saladax-biomedical-expands-distribution-my5-fu-spain-portugal/937/
Committed to advancing the life sciences and improving the lives of Pennsylvanians through innovations in healthcare and enhanced economic opportunity. Since 2002, we have been actively funding healthcare technology companies in their very earliest stages, from emerging entities and companies seeking to expand or relocate, to university-based researchers or technology development groups. www.lsgpa.com
No comments:
Post a Comment